Compare GSK plc (GSK) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.46 (market cap $73.20B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| GSK | VTIP | |
|---|---|---|
Market Cap | $91.88B | $73.20B |
Volume | 7,730,529 | 2,511,360 |
Sector | Health | — |
52-Week High | $61.18 | $50.46 |
52-Week Low | $43.24 | $48.38 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.46 with no change in the last session. The technical outlook is bearish based on moving averages, though oscillators signal bullish momentum with RSI levels in oversold territory. Recent news highlights its role as a hedge against inflation and rising rates, with institutional investors increasing positions. Key support is at $48, with resistance at $49.
The outlook for VTIP is supported by its design to mitigate inflation risk amid persistent price pressures, but it faces headwinds from Federal Reserve policy uncertainty. Investment appeal lies in its short-duration TIPS focus, reducing interest-rate sensitivity, while risks include potential inflation moderation and real yield volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
